Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine effects on HDL function in acute coronary syndrome
ChiCTR2000039188Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of colchicine in acute coronary syndrome (ACS) (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Myocardial enzyme, NT-proBNP and 22 more. Started Sep 2020; status: recruiting.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2000039188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039188.